Swedish Orphan Biovitrum AB

Sobi (Swedish Orphan Biovitrum) is an international biopharmaceutical company headquartered in Stockholm, dedicated to transforming the lives of people with rare diseases. Focused on haematology, immunology and specialty care, its portfolio includes Elocta and Alprolix (haemophilia), Doptelet (ITP/CLD), Kineret, Synagis (RSV) and Gamifant (pHLH). Employs ~1,800 people across Europe, North America, the Middle East and Asia, with 2024 revenues of SEK 26 billion. Listed on Nasdaq Stockholm.